Alexis Nicole Groce Mackin, MS, OTR/L in Harrington, DE - Occupational Therapist

Alexis Nicole Groce Mackin, MS, OTR/L is a Occupational Therapist based in Harrington, Delaware. Alexis Nicole Groce Mackin is licensed to practice in Delaware (license number U1-0001958) and her current practice location is 2015 Sandbox Rd, Harrington, Delaware. She can be reached at her office (for appointments etc.) via phone at (302) 535-3164.

NPI number for Alexis Nicole Groce Mackin is 1760957559 and her current mailing address is 2015 Sandbox Rd, Harrington, Delaware. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1760957559.

Contact Information

	Alexis Nicole Groce Mackin, MS, OTR/L
	2015 Sandbox Rd, Harrington, DE 19952-2666
	(302) 535-3164
	Not Available

Healthcare Provider's Profile

Full Name	Alexis Nicole Groce Mackin
Gender	Female
Speciality	Occupational Therapist
Location	2015 Sandbox Rd, Harrington, Delaware
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1760957559
Provider Enumeration Date: 10/08/2018
Last Update Date: 09/15/2023

Medical Identifiers

Medical identifiers for Alexis Nicole Groce Mackin such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1760957559	NPI	-	NPPES
U1-0001958	Other	DE	STATE OF DELAWARE

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225X00000X	Occupational Therapist	U1-0001958 (Delaware)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Alexis Nicole Groce Mackin is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Alexis Nicole Groce Mackin, MS, OTR/L 2015 Sandbox Rd, Harrington, DE 19952-2666 Ph: () -	Alexis Nicole Groce Mackin, MS, OTR/L 2015 Sandbox Rd, Harrington, DE 19952-2666 Ph: (302) 535-3164

News Archive

US FDA approves MRI especially for newborns

The U.S. Food and Drug Administration yesterday approved the first magnetic resonance imaging (MRI) device that can be specifically used in neonates or newborn babies. These MRI devices would be used for imaging of the brains and head in neonates who are admitted to the neonatal intensive care units (NICU) where they are necessary.

Opana ER – a long acting opioid painkiller, to be pulled from the markets as per FDA directive

The US Food and Drug Administration this Thursday (8th June 2017) directed pharmaceutical company Endo Pharmaceuticals to remove one of its powerful opioid painkillers Opana ER, that provides a long term relief of pain but also poses a risk of drug abuse.

Roundup: Calif. deciding on exchange name; Further scrutiny for Calif. adult day care eligibility; N.C. nurses embracing evidence-based practices

As states work to comply with the federal health care law, many are designing their insurance exchanges, where people will be able to shop for coverage. But just the word 'exchange' sounds to many like off-putting government-speak, and some states are eager to come up with a more appealing name for these new marketplaces. Peter Lee, who directs California's Health Benefit Exchange, says it's up for a new name, and he says they want it to sound fresh, dynamic and innovative.

Positive phase III clinical trial data of NovoCure's NovoTTF device for recurrent GBM presented at ASCO

Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, non-invasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments.

Why do we procrastinate?

The research comes at an opportune moment as the start of a new year is traditionally a time when many of us earnestly pledge to make a fresh start in some way - by getting fit, losing weight, giving up smoking and so on.

Alexis Nicole Groce Mackin, MS, OTR/L - Occupational Therapist in Harrington, DE